Article Information
History
- February 8, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Cosmin A. Bejan1,*,
- Katherine N. Cahill2,
- Patrick J. Staso2,
- Leena Choi3,
- Josh F. Peterson1,4 and
- Elizabeth J. Phillips5,6,7
- 1Department of Biomedical Informatics; Vanderbilt University Medical Center; Nashville, USA
- 2Department of Medicine; Division of Allergy, Pulmonary and Critical Care Medicine; Vanderbilt University Medical Center; Nashville, USA
- 3Department of Biostatistics; Vanderbilt University Medical Center; Nashville, USA
- 4Department of Medicine; Vanderbilt University Medical Center; Nashville, USA
- 5Department of Pathology, Microbiology and Immunology; Vanderbilt University Medical Center; Nashville, USA
- 6Department of Medicine; Division of Infectious Diseases; Vanderbilt University Medical Center; Nashville, USA
- 7Department of Pharmacology; Vanderbilt University Medical Center; Nashville, USA
- ↵*Corresponding author:
Cosmin A. Bejan, PhD, Department of Biomedical Informatics, Vanderbilt University School of Medicine, 2525 West End Avenue, Suite 1500, Nashville, TN 37232, USA, Phone: (615) 875-2422, E-mail: adi.bejan{at}vanderbilt.edu
Posted February 08, 2021.
DrugWAS: Leveraging drug-wide association studies to facilitate drug repurposing for COVID-19
